Introduction
============

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that can potentially lead to disability; in fact, about 30% of patients affected by RA are no longer able to perform a job after 3 years of disease.[@b1-dddt-11-985] The antitumor necrosis factor-α (TNF-α) agents, called "biological agents", represent the most effective therapy available for patients with RA.[@b2-dddt-11-985] Biologic drugs are currently the strongest immunosuppressive drugs able to induce remission in RA, as they inhibit the proinflammatory cytokines further expressed during the acute phase of illness. However, their economic cost is high, and the biological risk of prolonged treatment remains uncertain. Preliminary evidence of loss of efficacy over time is emerging, and therefore rotation between the available biological drugs is often necessary to maintain a good clinical response.[@b3-dddt-11-985] Another unsolved problem is to know how long the patient should take the biologic medications; in addition, in the early stages, once the remission of the disease is obtained, it is unclear whether it is correct to suspend the biological therapy. Biologic drugs are now used as second-line drug in case of failure of conventional therapy with Methotrexate, A Cyclosporin, or Leflunomide, considered as first-line therapy and ientified as disease-modifying antirheumatic drugs (DMARDs).[@b4-dddt-11-985]

One of the purposes of the medical scientific community now is to get not only a subjective and objective improvement of the symptomatic relief, but also the remission of the disease and the achievement of the lowest level of activity (low disease activity, LDA).[@b5-dddt-11-985]

In this context, identifying the therapeutic strategies that may maintain remission or the LDA either with therapy with DMARDs (first line) or with the biological (second line) is the aim of the scientific community. In addition to the two options of continuing treatment with DMARDs or biologic drugs, after achieving remission or LDA, with the related economic costs and safety issues, there is a third option of biological regulation with low doses of anti-inflammatory cytokines regulators.

At the present state of knowledge, there are numerous data on both the murine and human models suggesting that it might be possible to intervene directly in the inflammatory process of RA through the use of certain cytokines and inhibitors able to modulate at least in part the complex network of cytokines involved in the pathogenesis of RA.[@b6-dddt-11-985],[@b7-dddt-11-985] The contemporary use of more than one biologic drug at standard dosage is actually impossible, as such a combination would be burdened by severe side effects.[@b8-dddt-11-985] On the contrary, low doses (10 fg/mL) of cytokines, already in use in Italy, in the United States, and in several other countries for various diseases, may allow their simultaneous use with superior efficacy to their single use without causing serious adverse effect. This could allow a more physiological, though slower, modulation of the pathological process.[@b9-dddt-11-985] RA is an immune-mediated disease with an imbalance of the immune system Th1/Th2 in favor of the Th1 clone, with cytokines TNF-α, Interleukin (IL)-6, IL-1 increase, and reduction of IL-4 and IL-10.[@b10-dddt-11-985],[@b11-dddt-11-985] In this condition, the combined use of low doses of IL-4, IL-10, and anti-IL-1 antibodies may contribute to maintaining the balance of the immune system.

In addition, according to studies on animals and human beings, the particular process of sequential kinetic activation (SKA) allows us to amplify the therapeutic effects without adverse effects.[@b12-dddt-11-985],[@b13-dddt-11-985]

Gariboldi et al[@b14-dddt-11-985] recently published a study in which oral administration of low-dose IL-12 plus Interferon-γ is able to quench the bronchial hyperresponsiveness in mice. The antiasthma effect was confirmed by histological analysis of the lungs and by bronchoalveolar lavage.

The aim of this trial is to evaluate whether the use of low-dose SKA IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) in patients affected by RA can maintain LDA or remission obtained after biological therapy or DMARDs, with a treatment and observation period of 12 months.

Materials and methods
=====================

Study design
------------

This is a randomized, open, two arms, active-controlled, prospective, Phase IV trial to evaluate the maintenance of LDA or remission with the use of low-dose SKA IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL). The treatment and observation period was 12 months ([Figure 1](#f1-dddt-11-985){ref-type="fig"}).

Inclusion criteria for patient enrollment: RA diagnosed according to ACR criteria[@b15-dddt-11-985]Duration of disease \<3 yearsDisease activity score of 28 joints (DAS28) \<3.2 after biologic drugs and/or DMARD therapyPatients who have reached the state of remission or LDA after treatment with biologic drugs (Adalimumab, Etanercept, Infliximab, Certolizumab pegol, Golimumab) or after one therapy with DMARDsPatients able to adhere to the procedures of the study and fill out questionnairesWritten informed consent received from each participants.

Exclusion criteria were the following: Age \<18 yearsDisease duration \>3 yearsPresence of comorbidities that would contraindicate therapy with biological agents or immunosuppressant drugs (infection in progress, or a history of tuberculosis or cancer).

The study was conducted in accordance with the principles of the Declaration of Helsinki (Seoul 2008) and Good Clinical Practice guidelines (CPMP/ICH/135/95), and the study and the consent procedures were approved by the Ethics Committee of the San Pietro Fatebenefratelli Hospital, Rome. The trial was registered with EudraCT number 2011-003016-23 through the database of the National Clinical Trials Monitoring Center Database (Osservatorio, OsSC) of the Italian Medicines Agency.

Study procedure
---------------

Subjects were enrolled at the Rheumatology Unit, San Pietro Hospital Fatebenefratelli, Rome, between July 2011 and March 2014. A total of 52 subjects were screened and 39 were enrolled and randomized as shown in the clinical trial flow diagram ([Figure 1](#f1-dddt-11-985){ref-type="fig"}). In detail, five males and 34 females (mean age: 55.19) with RA, diagnosed according to ACR criteria, were enrolled in the study. At the screening visit, the following actions were performed: verification of criteria for inclusion and exclusion in the study, collection of demographic characteristics and complete anamnesis and signature of written informed consent was received from each subject for this study. At baseline visit (T0), clinical parameters such as DAS28, clinical disease activity index (CDAI), simplified disease activity index (SDAI), swollen and tender joints, global health assessment (GHA), and pain visual analog scale (VAS) were evaluated, and laboratory testing such as erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and C-reactive protein (CRP) was performed. Such parameters were then evaluated every 3 months together with an assessment of side effects. In addition, the use of NSAIDs, whose use was permitted (Celecoxib), was assessed at every control visit.

Outcomes
--------

The primary endpoint of this study is to assess whether and how long the association of low-dose SKA IL-4, IL-10, and anti-IL-1 antibodies (10 fg/mL) can maintain LDA obtained by previous treatment with anti-TNF-α biologic agents and/or DMARDs by the evaluation of activity parameters such as DAS28, CDAI, and SDAI.

As secondary endpoints we also evaluated at baseline and every 3 months pain VAS rating on a 0--10 scale, GHA, erythrosedimentation rate (ESR, using the Westergren method), CRP levels, and NSAIDs consumption, and we aimed to identify the eventual predictors of the effectiveness of the association of low-dose SKA IL-4, IL-10, anti-IL-1 antibodies (10 fg/mL) in the maintenance of remission obtained with biological drugs. We also performed an overall safety evaluation of drugs administered in the two arms.

Treatments
----------

SKA-cytokines/antibodies were prepared by GUNA Laboratories (GUNA S.p.a., Milan, Italy) using the standardized method.[@b13-dddt-11-985] IL-4, IL-10, and anti-IL-1 antibodies were activated by sequential serial dilution (1:100) in 30% hydroalcoholic solution and kinetically energized by a shaking procedure (vertical shaking; 10 cm motion range; shaking speed corresponding to 100 oscillations in 10 seconds). Subjects who satisfied the eligibility criteria were randomly allocated to Group A (Cytokines arm) or Group B (DMARDs arm), and identified by their initials and a serial number.

Group A is made up of patients who achieved an LDA or remission of the disease after 6--8 months of biological therapy or conventional therapy with DMARDs, after withdrawing biologic drugs or conventional therapy, and were treated with Guna-IL-4, Guna-IL-10, and Guna-Anti-IL-1 formulated at a concentration of 10 fg/mL SKA. Each preparation was orally administered at a dose of 20 drops/d for 12 consecutive months. The use of NSAID (Celecoxib 200 mg/d) has been permitted on request. Group B is made up of patients who achieved LDA or remission of the disease after 6--8 months of biological therapy or conventional therapy with DMARDs that will continue with conventional therapy (DMARDs). The use of NSAID (Celecoxib 200 mg/d) has been permitted on request. Patients in Group A were permitted to continue DMARDs-based therapy.

Randomization
-------------

Subjects who satisfied the eligibility criteria were randomized using software with a 60 random list for the two groups (A and B) in a 1:1 ratio. Block randomization was performed with a block size of 4. The subjects were assigned to Group A or B, according to the sequential order of enrollment.

Statistical analysis
--------------------

A descriptive analysis was performed for all the demographic variables and clinical features at baseline. Student's *t*-test for paired data was conducted to evaluate the clinical efficacy parameters (DAS28) of treatment at 12 months, compared to baseline. In case of violation of the assumptions underlying the aforementioned parametric statistical tests, the analysis was performed with a nonparametric method, in particular, the Wilcoxon test. The McNemar test was used in each group of patients to evaluate changes observed at different times for qualitative variables.

Laboratory data were analyzed using descriptive statistics (mean, standard error, minimum, and maximum) at each time of detection for assessment of tolerability. Changes in laboratory parameters between baseline and the time T12 were assessed using a parametric method (Student's *t*-test for dependent samples) or, in the case of breach of commitments, a nonparametric method (the Wilcoxon test). The retention of patients in the state of LDA in each group was evaluated by the Kaplan--Meyer b curve.

Results
=======

Fifty-two subjects underwent screening. Thirty-nine of these were enrolled. Five patients did not complete the study ([Figure 1](#f1-dddt-11-985){ref-type="fig"}, [Table 1](#t1-dddt-11-985){ref-type="table"}). As for the main characteristics of patients at baseline, no differences were observed between the two groups, except for mean age, which turned out to be slightly lower in Group A.

Primary endpoint
----------------

The maintenance of LDA at 12 months is obtained in 66.7% of subjects treated with low-dose cytokines (Group A; n=10) and in 42.1% of patients treated with DMARDs (Group B; n=8); the difference between the groups is not statistically significant (Fisher's exact test: *P*=0.185)

In Group A, 2 subjects were treated at the same time with DMARDs (Methotrexate) and low-dose cytokines.

### DAS28

DAS28 values are similar in the two groups at baseline (Mann--Whitney *U*-test: *P*=0.3991) as well as at 12 months (Mann--Whitney *U*-test: *P*=0.1030). Group A maintains constant values of DAS28 (Friedman test: *P*=0.41604), while in Group B, DAS28 values are on the rise (Friedman test: *P*=0.00198), with a significant difference (test according to Conover: *P*\<0.05) between T0 and T9, T0 and T12, T3 and T9, and T3 and T12 ([Figure 2](#f2-dddt-11-985){ref-type="fig"}).

### CDAI

CDAI scores are similar in the two groups at baseline (Mann--Whitney *U*-test: *P*=0.7317) as well as at 12 months (Mann--Whitney *U*-test: *P*=0.0510). Group A shows a constant sealing over time (Friedman test: *P*=0.84645), while values are on the rise in Group B (Friedman test: *P*=0.00004), with a significant difference (test according to Conover: *P*\<0.05) between T0 and T6, T0 and T9, T0 and T12, T3 and T9, T3 and T12, T6 and T9, and T6 and T12 ([Figure 3](#f3-dddt-11-985){ref-type="fig"}).

### SDAI

The SDAI showed no statistical difference between the two groups at baseline (Mann--Whitney *U*-test: *P*=0.9223) as well as at 12 months (Mann--Whitney *U*-test: *P*=0.0790). Group A showed a constant intragroup sealing (Friedman test: *P*=0.56774), while a significant intragroup difference was shown in Group B (Friedman test: *P*\<0.00001 and test according to Conover: *P*\<0.05) between the following time points: T0 and T6, T9 and T0, T0 and T12, T3 and T9, T12 and T3, T6 and T9, and T6 and T12 ([Figure 4](#f4-dddt-11-985){ref-type="fig"}).

Secondary endpoint
------------------

### Pain VAS

The pain VAS values are similar between the two groups at both baseline visit (Mann--Whitney *U*-test: *P*=0.7336) and 12 months follow-up (Mann--Whitney *U*-test: *P*=0.1772). Patients maintain constant levels without any intragroup difference as shown by the Friedman test; *P*-values were, respectively, 0.79490 in Group A and 0.12474 in Group B ([Figure 5](#f5-dddt-11-985){ref-type="fig"}).

### GHA

GHA values did not show any statistical difference between the two groups at baseline (Mann--Whitney *U*-test: *P*=0.4998) and at 12 months (Mann--Whitney *U*-test: *P*=0.3269). Patients maintain constant values in both groups: Friedman test: *P*=0.19770 in Group A and Friedman test: *P*=0.05608 in Group B ([Figure 6](#f6-dddt-11-985){ref-type="fig"}).

### ESR

ESR mean values did not show any significant intergroup difference at baseline (Mann--Whitney *U*-test: *P*=0.7153) as well as at 12 months (Mann--Whitney *U*-test: *P*=0.0699). Similarly, no intragroup significant differences were reported; Friedman test *P*-values were, respectively, 0.53603 in Group A and 0.08022 in Group B ([Figure 7](#f7-dddt-11-985){ref-type="fig"}).

### CRP

The CRP mean values are lower in Group A at baseline (Mann--Whitney *U*-test: *P*=0.0078), but similar at 12 months without any significant statistical difference (Mann--Whitney *U*-test: *P*=0.0966). Patients show intragroup constant levels; Friedman test was, respectively, *P*=0.69002 in Group A and *P*=0.22356 in Group B ([Figure 8](#f8-dddt-11-985){ref-type="fig"}).

### NSAIDs (Celecoxib 200 mg/die) consumption evaluation

No differences were observed in the consumption of Celecoxib between two groups at any time point, although the small sample size, owing to the small percentage of patients needing to take this medication, does not allow certain conclusions to be drawn.

### Predictors of the effectiveness of cytokines association therapy in the maintenance of remission

Covariance analysis regarding the impact of the condition of LDA or remission in the results of DAS28 showed no statistically significant differences (Friedman test: *P*=0.530). Because of the small sample size, no statistical analysis was performed as for CDAI and SDAI.

Safety assessment
-----------------

A total of 34 patients were exposed to treatments during 12 months. Respectively, 15 subjects in Group A, composed of patients who achieved an LDA or remission of the disease after biological therapy or conventional therapy with DMARDs, were treated with Guna-IL-4, Guna-IL-10, and Guna-Anti-IL-1 formulated concentration 10 fg/mL, and 19 patients in the Group B, who similarly achieved an LDA or remission of the disease after biological therapy or conventional therapy with DMARDs, were treated with conventional therapy.

No adverse events were reported by investigators in both groups.

Discussion
==========

This is the first study using low-dose cytokine in RA, after those published on psoriasis. In fact, Roberti et al[@b9-dddt-11-985] studied the pharmacological activity and safety of three low-dose cytokines -- Guna-IL-4, Guna-IL-10, and Guna-IL-11 -- at a concentration of 10 fg/mL in patients affected by moderate-to-slight psoriasis vulgaris in a double-blind, randomized, placebo-controlled clinical trial involving 48 patients. They reported a psoriasis area severity index significant reduction in the 41 evaluated patients.

In this study, the maintenance of LDA or remission at 12 months is obtained, respectively, in 66.7% of subjects treated with low-dose cytokines (Group A) and in 42.1% of subjects treated with DMARDs (Group B).

Even though the results do not reach the primary endpoint, it is important to note that they cannot be considered conclusive as evaluated on a sample not sufficiently powerful (power is much lower than 80% because of the low number of subjects). However, there are sufficient reasons to believe that treatment with cytokines gives a better result in respect to the standard DMARDs-based therapy, considering the trend of the experimental arm.

Values of DAS28, CDAI, and SDAI seem to show a common behavior of the variables, eg, even if the sample was too small to detect intergroup differences, the nonparametric ANOVA (Friedman test) shows that substantially stable values of the variables have been maintained in Group A, whereas a significant increase is observed for Group B. More precisely, running a pairwise analysis (with Conover's test adjusted for multiple comparisons), we notice that increases, compared to baseline, begin to be significant (*P*\<0.05) at T9 for DAS28, at T6 for CDAI, and even at T6 for SDAI. Moreover, in Group A, values are kept at a lower degree of dispersion, as reported looking at box plots. Such differences were not observed in ESR and CRP levels, and these data are difficult to interpret, especially after having observed different trends in the two groups for all other observed indicators.

Taken together, these data suggest the opportunity to use low-dose SKA cytokine in RA. In particular, this study seems to suggest that the differences between the two groups emerge in the sixth month of treatment after the beginning of remission, when the group treated with low-dose SKA cytokines keeps the requirements of remission in a homogeneous manner, while the group treated with DMARDs gets progressively worse with a wide range of intragroup variability. The data seem to confirm the hypothesis that therapy with low-dose SKA cytokines might induce a progressive regulation and a stabilization of the immune system that may justify the smaller dispersion of the sample at least in a subset of patients. As for the differences in terms of results obtained in the study on psoriasis in respect to the results obtained in this study, it is difficult to explain why this kind of therapy may be more effective in a pathology such as psoriasis, but again the small number of patients included in this study as well as the deep pathogenic differences between psoriasis and RA may explain this dissimilarity.

Although further studies are needed, these preliminary data allow us to hypothesize that one out of four patients could benefit from the low-dose SKA treatment to maintain remission. These data suggest that protocols need to be developed aimed at identifying predictors of response.

That difference in maintaining the low levels of DAS28 can be estimated as 25%, since low level is actually verified at T12 in 10 of 15 patients (67%) and in 8 of 19 patients (42%).

From the perspective of clinical practice, therapy with low-dose SKA cytokines should be considered among the tools for the management of disease remission obtained with biological agents in RA patients, as well as for dermatologists in vitiligo management.[@b16-dddt-11-985] The availability of a systemic treatment based on the oral administration of low-dose activated signaling molecules represents an opportunity for the specialists to overcome some specific pitfalls of currently available therapeutic protocols. It responds to the need for new strategies for the treatment of RA with biological agents, or the target of cytokines combination, as well as contributing to the evidence on the issue of management of remission in RA. Although several drugs with different mechanisms of action are available for the treatment of RA, a significant percentage of patients show an inadequate response to biological treatment. It can be hypothesized that treatment failure could be due to the multifactorial nature of the disease or to the existence of several subsets of disease.

Consequently, new research approaches have to be introduced with the aim of gaining the target of clinical response in all RA patients. Taking inspiration from the oncologic or cardiologic fields, we could hypothesize a new regimen of treatment with combined low-dose or ultralow-dose biological agents to avoid important side effects but acting simultaneously on different targets, since literature data of a combination of biological agents administered at the registered dose are not safe.[@b17-dddt-11-985]--[@b21-dddt-11-985] These data confirm the safety profile of these molecules, even in combination, as reported in other studies, and in addition, this is the first study to show data for a continuous period of 12 months.[@b8-dddt-11-985]

The low cost of the low-dose SKA cytokines is another factor to be taken into account for the possibility of extending the treatments to a greater number of patients, considering also the optimal safety profile.

This clinical trial presents some limitations. First, the number of patients is not sufficient to establish statistically significant differences, and a larger study population is needed to increase the certainty of results. Even if follow-up times are enough to show a different trend between the groups, a longer follow-up could give us more information about the duration on LDA in the low-dose cytokine group. Finally, the study did not compare treatments with a placebo arm.

However, these data are consistent with the trend toward a personalization of treatment in RA patients, according to current international literature and good clinical practice.

Conclusion
==========

In conclusion, the use of low-dose SKA cytokines/antibodies (IL-4, IL-10, and anti-IL-1) simultaneously administered orally has shown a good efficacy in RA patients in maintaining LDA at least in a subset of patients who have undergone remission after biological drugs or conventional therapy. The safety profile has been confirmed excellent since no adverse event was reported in any of the RA patients treated. The availability of low-dose products containing diluted and SKA-activated cytokines represents a new opportunity to explore for the global management of RA patients also in the era of biological agents.
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![Flowchart diagram reporting study enrollment, allocation, dropouts distribution, and patients included for analysis.\
**Abbreviation:** DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig1){#f1-dddt-11-985}

![DAS28 in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Note:** Squares report mean value and standard deviation of DAS28 score at various time points.\
**Abbreviations:** DAS, disease activity score; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig2){#f2-dddt-11-985}

![CDAI in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Note:** Squares report mean value and standard deviation of CDAI score at various time points.\
**Abbreviations:** CDAI, clinical disease activity index; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig3){#f3-dddt-11-985}

![SDAI in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Note:** Squares report mean value and standard deviation of SDAI score at various time points.\
**Abbreviations:** SDAI, simple disease activity index; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig4){#f4-dddt-11-985}

![VAS in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Abbreviations:** VAS, visual activity score on a scale 1--10; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig5){#f5-dddt-11-985}

![GHA in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Abbreviations:** GHA, global health assessment; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig6){#f6-dddt-11-985}

![ESR in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Abbreviations:** ESR, erythrosedimentation rate; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig7){#f7-dddt-11-985}

![CRP in patients receiving low-dose cytokines or conventional therapy as evaluated at baseline or every 3 months.\
**Note:** Squares report mean value and standard deviation of CRP score at various time points.\
**Abbreviations:** CRP, C reactive protein; DMARDs, disease-modifying antirheumatic drugs.](dddt-11-985Fig8){#f8-dddt-11-985}

###### 

Demographic and clinical characteristics of patients included in the study at T0

                                  Group A         Group B
  ------------------------------- --------------- ---------------
  Subjects (n)                    15              19
  Age                             47.08±11.11     63.3±11.48
  Females (%)                     92.85           85.71
  Disease duration (years)        3.58±1.62       2.56±0.82
  Previous DMARDs therapy (n)     2/15 (13.3%)    3/19 (15.8%)
  Previous biologic therapy (n)   13/15 (86.7%)   16/19 (84.2%)
  DAS28                           2.62            2.46
  CDAI                            6.14            2.80
  SDAI                            4.99            2.23
  Swollen joints                  0.50            0.14
  Tender joints                   1.33            1.14
  GHA                             21.56           16.50
  ESR (mm/h)                      13.67           14.26
  CRP (mg/dL)                     0.70            2.18
  RF                              50.85           83.78
  VAS (0--10)                     3.38            3.08

**Notes: Group A:** patients achieving remission or LDA undergoing low dose cytokines therapy. **Group B:** patients achieving remission or LDA undergoing conventional DMARDs therapy.

**Abbreviations:** T0, baseline visit; DMARDs, disease-modifying antirheumatic drugs; DAS, disease activity score; CDAI, clinical disease activity index; LDA, low disease activity; SDAI, simplified disease activity index; GHA, global health assessment; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; VAS, visual analog scale; SD, standard deviation.
